Recombinant Human HRG Protein, C-10*His tag_天津卡梅德科技发展有限公司

Recombinant Human HRG Protein, C-10*His tag

产品编号

KRP097

别名

组氨酸富含糖蛋白, Histidine-rich glycoprotein , Histidine-proline-rich glycoprotein, HPRG,

规格

20ug
50ug
100ug
200ug
1mg

DATASHEET MSDS

立即询价加入询价列表大包装定制

产品介绍

Catalog Number	KRP097
Alias	组氨酸富含糖蛋白, Histidine-rich glycoprotein , Histidine-proline-rich glycoprotein, HPRG,
Size	20ug, 50ug, 100ug, 200ug, 1mg
Product Description	Human HRG(19-525 aa)
Molecular Name	HRG
Product Introduction	组氨酸富含糖蛋白在血清中发挥重要生物学功能，调节免疫和修复。。
Molecular Weight	80-85 kDa
Expression System	HEK293F Cells
Species	Human
Concentration	联系销售经理获得最新批次的浓度
Purity	≥90%
SDS-PAGE
Purification	Affinity Purification
Uniprot ID	P04196
Storage Condition	Store the product under sterile conditions after opening at -80℃ for 12 months. Store the lyophilized powder at -20℃. Avoid repeated freeze-thaw cycles.
Formulation	Supplied in PBS
Shipping Condition	This product is shipped on ice packs or dry ice.
Background	Plasma glycoprotein that binds a number of ligands such as heme, heparin, heparan sulfate, thrombospondin, plasminogen, and divalent metal ions. Binds heparin and heparin/glycosaminoglycans in a zinc-dependent manner. Binds heparan sulfate on the surface of liver, lung, kidney and heart endothelial cells. Binds to N-sulfated polysaccharide chains on the surface of liver endothelial cells. Inhibits rosette formation. Acts as an adapter protein and is implicated in regulating many processes such as immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis. Mediates clearance of necrotic cells through enhancing the phagocytosis of necrotic cells in a heparan sulfate-dependent pathway. This process can be regulated by the presence of certain HRG ligands such as heparin and zinc ions. Binds to IgG subclasses of immunoglobins containing kappa and lambda light chains with different affinities regulating their clearance and inhibiting the formation of insoluble immune complexes. Tethers plasminogen to the cell surface. Binds T-cells and alters the cell morphology. Modulates angiogenesis by blocking the CD6-mediated antiangiongenic effect of thrombospondins, THBS1 and THBS2. Acts as a regulator of the vascular endothelial growth factor (VEGF) signaling pathway; inhibits endothelial cell motility by reducing VEGF-induced complex formation between PXN/paxillin and ILK/integrin-linked protein kinase and by promoting inhibition of VEGF-induced tyrosine phosphorylation of focal adhesion kinases and alpha-actinins in endothelial cells. Also plays a role in the regulation of tumor angiogenesis and tumor immune surveillance. Normalizes tumor vessels and promotes antitumor immunity by polarizing tumor-associated macrophages, leading to decreased tumor growth and metastasis. {ECO:0000269\|PubMed:11134179, ECO:0000269\|PubMed:12235005, ECO:0000269\|PubMed:14744774, ECO:0000269\|PubMed:15220341, ECO:0000269\|PubMed:15313924, ECO:0000269\|PubMed:16436387, ECO:0000269\|PubMed:16489009, ECO:0000269\|PubMed:19285951, ECO:0000269\|PubMed:19535045, ECO:0000269\|PubMed:19712047, ECO:0000269\|PubMed:19903770, ECO:0000269\|PubMed:20573803, ECO:0000269\|PubMed:21215706, ECO:0000269\|PubMed:21304106}.
Endotoxin	< 0.1 EU per ug
Biological Activity	Measured by its ability to support the adhesion of MOLT‑4 human acute lymphoblastic leukemia cells. When 1 x 10^5 cells/well are added to Recombinant Human HPRG coated plates, adhesion is induced in a dose-dependent mannerin the presence of Concanvalin A.
Product Declaration	该产品仅供科研使用，不可直接用于人体或注射。